Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Iambic official newsroom · Indexed industry source record · Source published: Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:58 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
In nonclinical studies, IAM217 was observed to have potent and selective target engagement with a favorable drug-drug interaction profile IAM217 is believed to be brain penetrant, producing regression of established intracranial tumors in a preclinical model IAM217 was designed using Iambic's molecular superintelligence platform which included structural enablement using NeuralPLexer and without a
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.